Sign in

    Hiro Nagayumi

    Research Analyst at Cantor Fitzgerald

    Hiro Nagayumi is an Equity Research Analyst at Cantor Fitzgerald with a specialization in biotechnology and biopharmaceutical sectors. He covers a range of emerging and mid-cap biotech companies, providing detailed investment analysis and research recommendations to institutional clients. Nagayumi began his career in equity research and joined Cantor Fitzgerald as an analyst, having previously held associate roles focused on healthcare and life sciences analysis at other firms. He holds industry-standard securities licenses and maintains active FINRA registration.

    Hiro Nagayumi's questions to AGIOS PHARMACEUTICALS (AGIO) leadership

    Hiro Nagayumi's questions to AGIOS PHARMACEUTICALS (AGIO) leadership • Q1 2025

    Question

    Hiro Nagayumi from Cantor Fitzgerald asked for the rationale behind initiating a Phase II study for tebapivat in sickle cell disease ahead of receiving the Phase III data for PYRUKYND (mitapivat) in the same indication.

    Answer

    CMO Dr. Sarah Gheuens explained the decision was driven by promising Phase I data for tebapivat. CCO Tsveta Milanova added that the large sickle cell market can support multiple therapies, as not all patients respond to a single agent. Starting the trial now allows Agios to gather data on both assets, enabling a more informed strategy for building a broader sickle cell franchise and serving a larger patient population in the long term.

    Ask Fintool Equity Research AI